About the $ big-pharma re-patriation:
Does anyone know much fact about this ? Obviously one theory is that the PFE / MICU deal is the first evidence. Does the money have to be front-end loaded for deals/partnerships, or what are the IRS rules on it (its a tax-break) ?
Apparently it's a 100$bn re-patriation - do the companies (PFE, WYE, MRK, SGP, BMY, DNA, BIIB, etc) have to submit plans on what they intend to do - is this public information once submitted ? Is there a time-frame/window ? I hardly suppose it will identify the targets, LoL, but might specify the sizes of deals, and whether acquisitions are targeted.
Market Data 
Markets 
AI
